### Analysis

The earnings call for Amgen Inc. revealed several key points that could impact the stock price in the short term. The company reported strong financial performance, but there were some notable concerns and uncertainties. The delayed launch and reimbursement issues with Prolia, the impact of healthcare reform, and the potential for further downward pressure from REMS on ESAs were highlighted. Additionally, the company's guidance for the fourth quarter and the full year was slightly lower than expected, which could lead to short-term volatility. Overall, while the company's pipeline and strategic initiatives were praised, the immediate concerns around Prolia and ESAs could create uncertainty in the market.

### Conclusion

The short-term impact on Amgen's stock price is likely to be negative due to the uncertainties surrounding Prolia's launch and reimbursement, as well as the potential for further downward pressure on ESAs from REMS. The company's guidance for the fourth quarter and the full year was also slightly lower than expected, which could lead to further short-term volatility. Therefore, the stock price is likely to experience a negative impact in the next 1-2 weeks.

[-1]